Publication | Closed Access

Targeted Busulfan therapy with a steady-state concentration of 600–700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant

Hematological MalignancyCell TherapyTransplantationSickle Cell DiseaseBone Marrow TransplantImmunologyHematologyMedicineCell TransplantationBusulfan Therapy